Stock Events

Stock Events

Oncolytics Biotech 

€0.000000
105
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31JulExpected
Q1 2026
Next
-0.07
-0.06
-0.05
-0.04
Expected EPS
-0.04660503619200001
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ONYN.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap201.93B
Amgen is involved in developing oncology treatments, including oncolytic virus therapies, directly competing with Oncolytics Biotech's approach to cancer treatment.
Merck
MRK
Mkt Cap319.99B
Merck's extensive portfolio in oncology, including immunotherapy treatments, positions it as a competitor in the cancer treatment space, overlapping with Oncolytics Biotech's market.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb offers a range of cancer treatments, including immunotherapies that compete with Oncolytics Biotech's viral-based cancer therapies.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, with its focus on oncology and viral treatments, competes in the same space as Oncolytics Biotech, especially in the development of innovative cancer therapies.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a broad oncology division, including the development of treatments that could compete with Oncolytics Biotech's oncolytic virus therapy approach.
Novavax
NVAX
Mkt Cap1.6B
Novavax, while primarily known for vaccines, is exploring cancer vaccine treatments that could potentially compete with Oncolytics Biotech's viral-based therapies.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical division Janssen, develops a variety of oncology treatments that could compete with Oncolytics Biotech's approach to cancer therapy.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals focuses on developing monoclonal antibodies for cancer treatment, a method that could be seen as complementary or competitive to Oncolytics Biotech's viral therapies.
Sorrento Therapeutics
SRNE
Mkt Cap303,204
Sorrento Therapeutics is involved in the development of new therapies for cancer, including approaches that could compete with or complement Oncolytics Biotech's oncolytic virus strategy.
Vir Biotechnology
VIR
Mkt Cap1.69B
Vir Biotechnology, while focusing on infectious diseases, is exploring the potential of using viral vectors for therapeutic purposes, which could intersect with Oncolytics Biotech's cancer treatment strategies.

About

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Show more...
CEO
Mr. Jared Kelly J.D., L.L.M.
Employees
29
Country
Canada
ISIN
CA6823108759

Listings

MU
DE
ONYN.MU
STU
DE
ONYN.STU
BOATS
BOATS
ONCY.BOATS
XNAS
US
ONCY

0 Comments

Share your thoughts

FAQ

What is Oncolytics Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Oncolytics Biotech stocks are traded under the ticker ONYN.STU.
When is the next Oncolytics Biotech earnings date?▼
Oncolytics Biotech is going to release the next earnings report on July 31, 2026.
What were Oncolytics Biotech earnings last quarter?▼
ONYN.STU earnings for the last quarter are -0.07 EUR per share, whereas the estimation was -0.04 EUR resulting in a -84.59% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Oncolytics Biotech have?▼
As of July 09, 2026, the company has 29 employees.
In which sector is Oncolytics Biotech located?▼
Oncolytics Biotech operates in the Health & Wellness sector.
When did Oncolytics Biotech complete a stock split?▼
Oncolytics Biotech has not had any recent stock splits.
Where is Oncolytics Biotech headquartered?▼
Oncolytics Biotech is headquartered in San Diego, Canada.